{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:51:09Z","timestamp":1773964269456,"version":"3.50.1"},"reference-count":236,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12032-021-01547-1","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T02:02:41Z","timestamp":1626400961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies"],"prefix":"10.1007","volume":"38","author":[{"given":"Yogita","family":"Chhichholiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhat","family":"Suman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-8592","authenticated-orcid":false,"given":"Anjana","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"issue":"9","key":"1547_CR1","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.3390\/ijms20092272","volume":"20","author":"B Medeiros","year":"2019","unstructured":"Medeiros B, Allan AL. Molecular mechanisms of breast cancer metastasis to the lung: clinical and experimental perspectives. Int J Mol Sci. 2019;20(9):2272.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1547_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1021\/acs.jproteome.6b00950","volume":"16","author":"Y-D Cai","year":"2017","unstructured":"Cai Y-D, et al. Identification of genes associated with breast cancer metastasis to bone on a protein\u2013protein interaction network with a shortest path algorithm. J Proteome Res. 2017;16(2):1027\u201338.","journal-title":"J Proteome Res"},{"issue":"1","key":"1547_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trecan.2015.07.009","volume":"1","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Massagu\u00e9 J. Surviving at a distance: organ-specific metastasis. Trends Cancer. 2015;1(1):76\u201391.","journal-title":"Trends Cancer"},{"key":"1547_CR4","volume-title":"Tumor progression and metastasis","author":"H Yazici","year":"2019","unstructured":"Yazici H, Akin B. Molecular genetics of metastatic breast cancer. In: Tumor progression and metastasis. London: IntechOpen; 2019."},{"issue":"6","key":"1547_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler IJ. The pathogenesis of cancer metastasis: the \u201cseed and soil\u201d hypothesis revisited. Nat Rev Cancer. 2003;3(6):453\u20138.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1547_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.18632\/oncotarget.2677","volume":"6","author":"J Budczies","year":"2015","unstructured":"Budczies J, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015;6(1):570\u201383.","journal-title":"Oncotarget"},{"issue":"1","key":"1547_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","volume":"75","author":"IT Gavrilovic","year":"2005","unstructured":"Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75(1):5\u201314.","journal-title":"J Neurooncol"},{"issue":"3","key":"1547_CR8","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1148\/radiol.2423051707","volume":"242","author":"A Mujoomdar","year":"2007","unstructured":"Mujoomdar A, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007;242(3):882\u20138.","journal-title":"Radiology"},{"issue":"5","key":"1547_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13402-017-0345-5","volume":"40","author":"M Yousefi","year":"2017","unstructured":"Yousefi M, et al. Lung cancer-associated brain metastasis: molecular mechanisms and therapeutic options. Cell Oncol. 2017;40(5):419\u201341.","journal-title":"Cell Oncol"},{"issue":"2","key":"1547_CR10","first-page":"98","volume":"8","author":"S Paget","year":"1989","unstructured":"Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989;8(2):98\u2013101.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"1547_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.semcancer.2012.03.007","volume":"22","author":"G Lorusso","year":"2012","unstructured":"Lorusso G, R\u00fcegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol. 2012;22(3):226\u201333.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"1547_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cytogfr.2006.07.002","volume":"17","author":"A Nicolini","year":"2006","unstructured":"Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006;17(5):325\u201337.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10","key":"1547_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri1703","volume":"5","author":"M Karin","year":"2005","unstructured":"Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749\u201359.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1547_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1158\/1078-0432.CCR-11-1532","volume":"18","author":"CH Hsing","year":"2012","unstructured":"Hsing CH, et al. Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome. Clin Cancer Res. 2012;18(3):713\u201325.","journal-title":"Clin Cancer Res"},{"issue":"2\u20133","key":"1547_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10911-007-9047-3","volume":"12","author":"X Lu","year":"2007","unstructured":"Lu X, Kang Y. Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2007;12(2\u20133):153\u201362.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"26","key":"1547_CR16","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1056\/NEJMra0805239","volume":"359","author":"AC Chiang","year":"2008","unstructured":"Chiang AC, Massagu\u00e9 J. Molecular basis of metastasis. N Engl J Med. 2008;359(26):2814\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"1547_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/cancers10060185","volume":"10","author":"M Tauro","year":"2018","unstructured":"Tauro M, Lynch CC. Cutting to the chase: how matrix metalloproteinase-2 activity controls breast-cancer-to-bone metastasis. Cancers. 2018;10(6):185.","journal-title":"Cancers"},{"issue":"3","key":"1547_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1566524017666170807144946","volume":"17","author":"R Bell","year":"2017","unstructured":"Bell R, Barraclough R, Vasieva O. Gene expression meta-analysis of potential metastatic breast cancer markers. Curr Mol Med. 2017;17(3):200\u201310.","journal-title":"Curr Mol Med"},{"issue":"2","key":"1547_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/bcr2831","volume":"13","author":"MA Blanco","year":"2011","unstructured":"Blanco MA, Kang Y. Signaling pathways in breast cancer metastasis - novel insights from functional genomics. Breast Cancer Res. 2011;13(2):206.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"1547_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","volume":"5","author":"Y Feng","year":"2018","unstructured":"Feng Y, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77\u2013106.","journal-title":"Genes Dis"},{"issue":"6","key":"1547_CR21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/bcr87","volume":"2","author":"DR Welch","year":"2000","unstructured":"Welch DR, Steeg PS, Rinker-Schaeffer CW. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res. 2000;2(6):408\u201316.","journal-title":"Breast Cancer Res"},{"key":"1547_CR22","first-page":"165","volume":"11","author":"MR Cominetti","year":"2019","unstructured":"Cominetti MR, Altei WF, Selistre-de-Araujo HS. Metastasis inhibition in breast cancer by targeting cancer cell extravasation. Breast Cancer (Dove Medical Press). 2019;11:165\u201378.","journal-title":"Breast Cancer (Dove Medical Press)"},{"issue":"6","key":"1547_CR23","first-page":"648","volume":"4","author":"Z Li","year":"2014","unstructured":"Li Z, et al. Methylation-associated silencing of MicroRNA-335 contributes tumor cell invasion and migration by interacting with RASA1 in gastric cancer. Am J Cancer Res. 2014;4(6):648\u201362.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"1547_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ijc.11553","volume":"108","author":"W Zhao","year":"2004","unstructured":"Zhao W, et al. Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. Int J Cancer. 2004;108(1):167\u20139.","journal-title":"Int J Cancer"},{"issue":"6","key":"1547_CR25","doi-asserted-by":"publisher","first-page":"e0127923","DOI":"10.1371\/journal.pone.0127923","volume":"10","author":"I Zandvakili","year":"2015","unstructured":"Zandvakili I, et al. Loss of RhoA exacerbates, rather than dampens, oncogenic K-Ras induced lung adenoma formation in mice. PLoS ONE. 2015;10(6):e0127923.","journal-title":"PLoS ONE"},{"issue":"32","key":"1547_CR26","doi-asserted-by":"publisher","first-page":"22151","DOI":"10.1074\/jbc.M114.556126","volume":"289","author":"H Kim","year":"2014","unstructured":"Kim H, Choi JA, Kim JH. Ras promotes transforming growth factor-\u03b2 (TGF-\u03b2)-induced epithelial-mesenchymal transition via a leukotriene B4 receptor-2-linked cascade in mammary epithelial cells. J Biol Chem. 2014;289(32):22151\u201360.","journal-title":"J Biol Chem"},{"issue":"2","key":"1547_CR27","first-page":"267","volume":"15","author":"EM Gilhooly","year":"1999","unstructured":"Gilhooly EM, Rose DP. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol. 1999;15(2):267\u201370.","journal-title":"Int J Oncol"},{"issue":"17","key":"1547_CR28","first-page":"5454","volume":"63","author":"MS Kim","year":"2003","unstructured":"Kim MS, et al. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res. 2003;63(17):5454\u201361.","journal-title":"Cancer Res"},{"issue":"15","key":"1547_CR29","doi-asserted-by":"publisher","first-page":"14675","DOI":"10.1074\/jbc.M411625200","volume":"280","author":"I Shin","year":"2005","unstructured":"Shin I, et al. H-Ras-specific activation of Rac-MKK3\/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem. 2005;280(15):14675\u201383.","journal-title":"J Biol Chem"},{"issue":"12","key":"1547_CR30","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1158\/0008-5472.CAN-06-0826","volume":"66","author":"SO Yoon","year":"2006","unstructured":"Yoon SO, Shin S, Mercurio AM. Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells. Cancer Res. 2006;66(12):6288\u201395.","journal-title":"Cancer Res"},{"issue":"1","key":"1547_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/jbmr.205","volume":"26","author":"M Ono","year":"2011","unstructured":"Ono M, et al. WISP-1\/CCN4 regulates osteogenesis by enhancing BMP-2 activity. J Bone Miner Res. 2011;26(1):193\u2013208.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1547_CR32","doi-asserted-by":"publisher","first-page":"e0171343","DOI":"10.1371\/journal.pone.0171343","volume":"12","author":"AM Sieuwerts","year":"2017","unstructured":"Sieuwerts AM, et al. Progressive APOBEC3B mRNA expression in distant breast cancer metastases. PLoS ONE. 2017;12(1):e0171343.","journal-title":"PLoS ONE"},{"issue":"3","key":"1547_CR33","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.bbrc.2016.08.148","volume":"478","author":"W Maruyama","year":"2016","unstructured":"Maruyama W, et al. Classical NF-\u03baB pathway is responsible for APOBEC3B expression in cancer cells. Biochem Biophys Res Commun. 2016;478(3):1466\u201371.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"1547_CR34","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.4049\/jimmunol.164.11.5952","volume":"164","author":"C Chizzolini","year":"2000","unstructured":"Chizzolini C, et al. Th2 cell membrane factors in association with IL-4 enhance matrix metalloproteinase-1 (MMP-1) while decreasing MMP-9 production by granulocyte-macrophage colony-stimulating factor-differentiated human monocytes. J Immunol. 2000;164(11):5952\u201360.","journal-title":"J Immunol"},{"issue":"4","key":"1547_CR35","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/jcb.10261","volume":"86","author":"EL Lagow","year":"2002","unstructured":"Lagow EL, Carson DD. Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha. J Cell Biochem. 2002;86(4):759\u201372.","journal-title":"J Cell Biochem"},{"issue":"31","key":"1547_CR36","doi-asserted-by":"publisher","first-page":"32633","DOI":"10.1074\/jbc.M400642200","volume":"279","author":"T Banno","year":"2004","unstructured":"Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem. 2004;279(31):32633\u201342.","journal-title":"J Biol Chem"},{"issue":"11","key":"1547_CR37","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1074\/mcp.M700120-MCP200","volume":"6","author":"LY Tang","year":"2007","unstructured":"Tang LY, et al. Quantitative phosphoproteome profiling of Wnt3a-mediated signaling network: indicating the involvement of ribonucleoside-diphosphate reductase M2 subunit phosphorylation at residue serine 20 in canonical Wnt signal transduction. Mol Cell Proteomics. 2007;6(11):1952\u201367.","journal-title":"Mol Cell Proteomics"},{"issue":"15","key":"1547_CR38","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.7150\/jca.44313","volume":"11","author":"CO Madu","year":"2020","unstructured":"Madu CO, et al. Angiogenesis in breast cancer progression, diagnosis, and treatment. J Cancer. 2020;11(15):4474\u201394.","journal-title":"J Cancer"},{"issue":"6436","key":"1547_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/364412a0","volume":"364","author":"KL Clark","year":"1993","unstructured":"Clark KL, et al. Co-crystal structure of the HNF-3\/fork head DNA-recognition motif resembles histone H5. Nature. 1993;364(6436):412\u201320.","journal-title":"Nature"},{"issue":"3","key":"1547_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1006\/geno.1997.5065","volume":"46","author":"W Korver","year":"1997","unstructured":"Korver W, et al. The human TRIDENT\/HFH-11\/FKHL16 gene: structure, localization, and promoter characterization. Genomics. 1997;46(3):435\u201342.","journal-title":"Genomics"},{"issue":"24","key":"1547_CR41","doi-asserted-by":"publisher","first-page":"10875","DOI":"10.1128\/MCB.25.24.10875-10894.2005","volume":"25","author":"IC Wang","year":"2005","unstructured":"Wang IC, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 2005;25(24):10875\u201394.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"1547_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/ncb1217","volume":"7","author":"J Laoukili","year":"2005","unstructured":"Laoukili J, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005;7(2):126\u201336.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"1547_CR43","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1593\/neo.04277","volume":"6","author":"C Pilarsky","year":"2004","unstructured":"Pilarsky C, et al. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004;6(6):744\u201350.","journal-title":"Neoplasia"},{"key":"1547_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2407-8-42","volume":"8","author":"N Bektas","year":"2008","unstructured":"Bektas N, et al. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer. 2008;8:42.","journal-title":"BMC Cancer"},{"issue":"44","key":"1547_CR45","doi-asserted-by":"publisher","first-page":"30695","DOI":"10.1074\/jbc.M109.007997","volume":"284","author":"YJ Chen","year":"2009","unstructured":"Chen YJ, et al. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem. 2009;284(44):30695\u2013707.","journal-title":"J Biol Chem"},{"issue":"9","key":"1547_CR46","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/ncb1767","volume":"10","author":"Z Fu","year":"2008","unstructured":"Fu Z, et al. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol. 2008;10(9):1076\u201382.","journal-title":"Nat Cell Biol"},{"issue":"19","key":"1547_CR47","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/emboj.2009.239","volume":"28","author":"HJ Park","year":"2009","unstructured":"Park HJ, et al. FoxM1, a critical regulator of oxidative stress during oncogenesis. Embo J. 2009;28(19):2908\u201318.","journal-title":"Embo J"},{"issue":"2","key":"1547_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ccr.2012.01.004","volume":"21","author":"A Chaudhary","year":"2012","unstructured":"Chaudhary A, et al. TEM8\/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell. 2012;21(2):212\u201326.","journal-title":"Cancer Cell"},{"issue":"18","key":"1547_CR49","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-13-1080","volume":"73","author":"D Chen","year":"2013","unstructured":"Chen D, et al. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Can Res. 2013;73(18):5821\u201333.","journal-title":"Can Res"},{"issue":"39","key":"1547_CR50","doi-asserted-by":"publisher","first-page":"13909","DOI":"10.1073\/pnas.0506517102","volume":"102","author":"Y Kang","year":"2005","unstructured":"Kang Y, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA. 2005;102(39):13909\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1547_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1747-1028-5-2","volume":"5","author":"CE Caldon","year":"2010","unstructured":"Caldon CE, Musgrove EA. Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div. 2010;5:2.","journal-title":"Cell Div"},{"issue":"1","key":"1547_CR52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s13046-019-1307-8","volume":"38","author":"R Zanin","year":"2019","unstructured":"Zanin R, et al. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1. J Exp Clin Cancer Res. 2019;38(1):313.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"1547_CR53","doi-asserted-by":"publisher","first-page":"e63419","DOI":"10.1371\/journal.pone.0063419","volume":"8","author":"SN Shah","year":"2013","unstructured":"Shah SN, et al. HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS ONE. 2013;8(5):e63419\u2013e63419.","journal-title":"PLoS ONE"},{"key":"1547_CR54","unstructured":"Martin, T.A., et al., Cancer invasion and metastasis: molecular and cellular perspective. In Madame Curie Bioscience Database [Internet]. 2013, Landes Bioscience."},{"key":"1547_CR55","doi-asserted-by":"publisher","first-page":"e27706","DOI":"10.7554\/eLife.27706","volume":"7","author":"SJ Vervoort","year":"2018","unstructured":"Vervoort SJ, et al. Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis. Elife. 2018;7:e27706.","journal-title":"Elife"},{"issue":"4","key":"1547_CR56","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ejmhg.2017.02.001","volume":"18","author":"T Kaur","year":"2017","unstructured":"Kaur T, et al. Identification of functional SNPs in human LGALS3 gene by in silico analyses. Egypt J Med Hum Genet. 2017;18(4):321\u20138.","journal-title":"Egypt J Med Hum Genet"},{"issue":"3","key":"1547_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.bbamcr.2015.08.008","volume":"1863","author":"PP Ruvolo","year":"2016","unstructured":"Ruvolo PP. Galectin 3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 2016;1863(3):427\u201337.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1547_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0304-4165(97)00086-X","volume":"1379","author":"J Ochieng","year":"1998","unstructured":"Ochieng J, et al. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochem Biophys Acta. 1998;1379(1):97\u2013106.","journal-title":"Biochem Biophys Acta"},{"issue":"24","key":"1547_CR59","doi-asserted-by":"publisher","first-page":"10045","DOI":"10.1158\/0008-5472.CAN-08-3224","volume":"68","author":"V Balan","year":"2008","unstructured":"Balan V, et al. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Can Res. 2008;68(24):10045\u201350.","journal-title":"Can Res"},{"issue":"1","key":"1547_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000454696","volume":"33","author":"E Pachmayr","year":"2017","unstructured":"Pachmayr E, Treese C, Stein U. Underlying mechanisms for distant metastasis - molecular biology. Visc Med. 2017;33(1):11\u201320.","journal-title":"Visc Med"},{"issue":"1","key":"1547_CR61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40880-017-0202-y","volume":"36","author":"HY Xie","year":"2017","unstructured":"Xie HY, Shao ZM, Li DQ. Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis. Chin J Cancer. 2017;36(1):36.","journal-title":"Chin J Cancer"},{"issue":"10","key":"1547_CR62","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1586\/14737140.8.10.1689","volume":"8","author":"Y Chen","year":"2008","unstructured":"Chen Y, Olopade OI. MYC in breast tumor progression. Expert Rev Anticancer Ther. 2008;8(10):1689\u201398.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"1547_CR63","first-page":"4281","volume":"17","author":"Y Tuo","year":"2018","unstructured":"Tuo Y, An N, Zhang M. Feature genes in metastatic breast cancer identified by MetaDE and SVM classifier methods. Mol Med Rep. 2018;17(3):4281\u201390.","journal-title":"Mol Med Rep"},{"issue":"2","key":"1547_CR64","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000489698","volume":"11","author":"E Barber","year":"2018","unstructured":"Barber E, et al. Orbital metastases from breast cancer with BRCA2 mutation: a case report and literature review. Case Rep Oncol. 2018;11(2):360\u20134.","journal-title":"Case Rep Oncol"},{"key":"1547_CR65","doi-asserted-by":"publisher","DOI":"10.15761\/ICST.1000228","author":"I Godet","year":"2017","unstructured":"Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017. https:\/\/doi.org\/10.15761\/ICST.1000228.","journal-title":"Integr Cancer Sci Ther"},{"issue":"20","key":"1547_CR66","first-page":"5603","volume":"60","author":"MS Tsai","year":"2000","unstructured":"Tsai MS, et al. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res. 2000;60(20):5603\u20137.","journal-title":"Cancer Res"},{"key":"1547_CR67","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.breast.2016.09.017","volume":"30","author":"O Awolaran","year":"2016","unstructured":"Awolaran O, Brooks SA, Lavender V. Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence. Breast. 2016;30:156\u201371.","journal-title":"Breast"},{"key":"1547_CR68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bcp.2019.03.031","volume":"164","author":"M Khoshakhlagh","year":"2019","unstructured":"Khoshakhlagh M, et al. Therapeutic potential of pharmacological TGF-\u03b2 signaling pathway inhibitors in the pathogenesis of breast cancer. Biochem Pharmacol. 2019;164:17\u201322.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1547_CR69","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10549-012-1986-8","volume":"134","author":"L-C Chen","year":"2012","unstructured":"Chen L-C, et al. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway. Breast Cancer Res Treat. 2012;134(3):989\u20131004.","journal-title":"Breast Cancer Res Treat"},{"issue":"7088","key":"1547_CR70","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/nature04695","volume":"440","author":"JT Erler","year":"2006","unstructured":"Erler JT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440(7088):1222\u20136.","journal-title":"Nature"},{"issue":"6824","key":"1547_CR71","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/35065016","volume":"410","author":"A M\u00fcller","year":"2001","unstructured":"M\u00fcller A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50\u20136.","journal-title":"Nature"},{"issue":"1","key":"1547_CR72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cytogfr.2012.08.007","volume":"24","author":"AK Singh","year":"2013","unstructured":"Singh AK, et al. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev. 2013;24(1):41\u20139.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"1547_CR73","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G","volume":"173","author":"M Mareel","year":"1997","unstructured":"Mareel M, et al. E-cadherin\/catenin\/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol. 1997;173(2):271\u20134.","journal-title":"J Cell Physiol"},{"issue":"20","key":"1547_CR74","first-page":"4722","volume":"55","author":"SJ Vermeulen","year":"1995","unstructured":"Vermeulen SJ, et al. Transition from the noninvasive to the invasive phenotype and loss of alpha-catenin in human colon cancer cells. Cancer Res. 1995;55(20):4722\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"1547_CR75","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1083\/jcb.113.1.173","volume":"113","author":"UH Frixen","year":"1991","unstructured":"Frixen UH, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113(1):173\u201385.","journal-title":"J Cell Biol"},{"key":"1547_CR76","first-page":"135","volume-title":"Cancer invasion and metastasis: molecular and cellular perspective","author":"T Martin","year":"2013","unstructured":"Martin T, et al. Cancer invasion and metastasis: molecular and cellular perspective. Austin: Landes Bioscience; 2013. p. 135\u201368."},{"issue":"1","key":"1547_CR77","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1152\/ajpcell.00238.2015","volume":"311","author":"SPH Chiang","year":"2016","unstructured":"Chiang SPH, Cabrera RM, Segall JE. Tumor cell intravasation. Am J Physiol Cell Physiol. 2016;311(1):C1\u201314.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"902","key":"1547_CR78","doi-asserted-by":"publisher","first-page":"612393","DOI":"10.3389\/fmed.2020.612393","volume":"7","author":"Y Qian","year":"2020","unstructured":"Qian Y, Shi L, Luo Z. Long non-coding RNAs in cancer: implications for diagnosis, prognosis, and therapy. Front Med. 2020;7(902):612393.","journal-title":"Front Med"},{"issue":"21","key":"1547_CR79","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1038\/onc.2014.226","volume":"34","author":"A Patsialou","year":"2015","unstructured":"Patsialou A, et al. Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGF\u03b2 in claudin-low breast tumor cells. Oncogene. 2015;34(21):2721\u201331.","journal-title":"Oncogene"},{"issue":"11","key":"1547_CR80","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/ncb1973","volume":"11","author":"S Giampieri","year":"2009","unstructured":"Giampieri S, et al. Localized and reversible TGF\u03b2 signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11(11):1287\u201396.","journal-title":"Nat Cell Biol"},{"issue":"37","key":"1547_CR81","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1038\/onc.2011.571","volume":"31","author":"I Keklikoglou","year":"2012","unstructured":"Keklikoglou I, et al. MicroRNA-520\/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-\u03baB and TGF-\u03b2 signaling pathways. Oncogene. 2012;31(37):4150\u201363.","journal-title":"Oncogene"},{"issue":"4","key":"1547_CR82","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/emboj.2008.294","volume":"28","author":"S Dangi-Garimella","year":"2009","unstructured":"Dangi-Garimella S, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J. 2009;28(4):347\u201358.","journal-title":"EMBO J"},{"issue":"19","key":"1547_CR83","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1158\/0008-5472.CAN-14-3394","volume":"75","author":"C Frankenberger","year":"2015","unstructured":"Frankenberger C, et al. Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of prometastatic tumor-associated macrophages. Can Res. 2015;75(19):4063\u201373.","journal-title":"Can Res"},{"issue":"23","key":"1547_CR84","doi-asserted-by":"publisher","first-page":"10959","DOI":"10.1158\/0008-5472.CAN-05-2228","volume":"65","author":"EI Deryugina","year":"2005","unstructured":"Deryugina EI, et al. Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Can Res. 2005;65(23):10959\u201369.","journal-title":"Can Res"},{"issue":"3","key":"1547_CR85","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.ajpath.2011.05.031","volume":"179","author":"EM Bekes","year":"2011","unstructured":"Bekes EM, et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol. 2011;179(3):1455\u201370.","journal-title":"Am J Pathol"},{"key":"1547_CR86","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.matbio.2015.04.004","volume":"44","author":"EI Deryugina","year":"2015","unstructured":"Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation-and metastasis-sustaining neovasculature. Matrix Biol. 2015;44:94\u2013112.","journal-title":"Matrix Biol"},{"issue":"9B","key":"1547_CR87","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1111\/j.1582-4934.2009.00764.x","volume":"13","author":"V Chabottaux","year":"2009","unstructured":"Chabottaux V, et al. Membrane-type 4 matrix metalloproteinase (MT4-MMP) induces lung metastasis by alteration of primary breast tumour vascular architecture. J Cell Mol Med. 2009;13(9B):4002\u201313.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"1547_CR88","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/onc.2011.240","volume":"31","author":"CH Chou","year":"2012","unstructured":"Chou CH, et al. MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis. Oncogene. 2012;31(4):458\u201368.","journal-title":"Oncogene"},{"issue":"3","key":"1547_CR89","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10555-019-09806-4","volume":"38","author":"MH Kubala","year":"2019","unstructured":"Kubala MH, DeClerck YA. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. Cancer Metastasis Rev. 2019;38(3):483\u201392.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"1547_CR90","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670\u201391.","journal-title":"Cell"},{"key":"1547_CR91","first-page":"113","volume":"9","author":"H Ahmed","year":"2015","unstructured":"Ahmed H, AlSadek DMM. Galectin-3 as a potential target to prevent cancer metastasis. Clinical medicine insights. Oncology. 2015;9:113\u201321.","journal-title":"Oncology"},{"issue":"15","key":"1547_CR92","doi-asserted-by":"publisher","first-page":"9842","DOI":"10.1074\/jbc.M114.602185","volume":"290","author":"K Wu","year":"2015","unstructured":"Wu K, et al. Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer. J Biol Chem. 2015;290(15):9842\u201354.","journal-title":"J Biol Chem"},{"issue":"9","key":"1547_CR93","doi-asserted-by":"publisher","first-page":"163","DOI":"10.21037\/atm.2018.04.35","volume":"6","author":"EM Brosnan","year":"2018","unstructured":"Brosnan EM, Anders CK. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med. 2018;6(9):163.","journal-title":"Ann Transl Med"},{"issue":"9","key":"1547_CR94","doi-asserted-by":"publisher","first-page":"e6896","DOI":"10.1371\/journal.pone.0006896","volume":"4","author":"LK Dunn","year":"2009","unstructured":"Dunn LK, et al. Hypoxia and TGF-\u03b2 drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE. 2009;4(9):e6896.","journal-title":"PLoS ONE"},{"issue":"1","key":"1547_CR95","doi-asserted-by":"publisher","first-page":"e30046","DOI":"10.1371\/journal.pone.0030046","volume":"7","author":"C Wendel","year":"2012","unstructured":"Wendel C, et al. CXCR4\/CXCL12 participate in extravasation of metastasizing breast cancer cells within the liver in a rat model. PLoS ONE. 2012;7(1):e30046.","journal-title":"PLoS ONE"},{"issue":"1","key":"1547_CR96","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cell.2008.01.046","volume":"133","author":"D Padua","year":"2008","unstructured":"Padua D, et al. TGF\u03b2 primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66\u201377.","journal-title":"Cell"},{"issue":"12","key":"1547_CR97","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/nrc3628","volume":"13","author":"N Reymond","year":"2013","unstructured":"Reymond N, d\u2019\u00c1gua BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer. 2013;13(12):858\u201370.","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"1547_CR98","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243s\u20139s.","journal-title":"Clin Cancer Res"},{"key":"1547_CR99","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-3-030-20301-6_7","volume":"1152","author":"RK Tahara","year":"2019","unstructured":"Tahara RK, et al. Bone metastasis of breast cancer. Adv Exp Med Biol. 2019;1152:105\u201329.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1547_CR100","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S8756-3282(01)00642-1","volume":"30","author":"A Parfitt","year":"2002","unstructured":"Parfitt A. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone. 2002;30(1):5\u20137.","journal-title":"Bone"},{"issue":"3","key":"1547_CR101","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jbmr.1547","volume":"27","author":"J Xiong","year":"2012","unstructured":"Xiong J, O\u2019Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012;27(3):499\u2013505.","journal-title":"J Bone Miner Res"},{"issue":"17","key":"1547_CR102","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1128\/MCB.00356-06","volume":"26","author":"Q Fu","year":"2006","unstructured":"Fu Q, Manolagas SC, O\u2019Brien CA. Parathyroid hormone controls receptor activator of NF-\u03baB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol. 2006;26(17):6453\u201368.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"1547_CR103","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cmet.2007.05.001","volume":"5","author":"S Tatsumi","year":"2007","unstructured":"Tatsumi S, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007;5(6):464\u201375.","journal-title":"Cell Metab"},{"issue":"4","key":"1547_CR104","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1349-7006.2011.02195.x","volume":"103","author":"L Mathot","year":"2012","unstructured":"Mathot L, Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci. 2012;103(4):626\u201331.","journal-title":"Cancer Sci"},{"issue":"2","key":"1547_CR105","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","volume":"10","author":"W Kozlow","year":"2005","unstructured":"Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005;10(2):169\u201380.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"1547_CR106","doi-asserted-by":"crossref","unstructured":"Coleman, R.E. and J.J. Seaman. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. in Seminars in oncology. 2001. Elsevier.","DOI":"10.1016\/S0093-7754(01)90260-X"},{"issue":"2","key":"1547_CR107","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50","volume":"10","author":"JM Chirgwin","year":"2000","unstructured":"Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Exp. 2000;10(2):159\u201378.","journal-title":"Crit Rev Eukaryot Gene Exp"},{"issue":"11","key":"1547_CR108","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrclinonc.2010.134","volume":"7","author":"T Onishi","year":"2010","unstructured":"Onishi T, et al. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol. 2010;7(11):641.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1547_CR109","first-page":"570","volume":"2","author":"TA Guise","year":"2002","unstructured":"Guise TA. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact. 2002;2(6):570\u20132.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"16","key":"1547_CR110","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655\u201364.","journal-title":"N Engl J Med"},{"issue":"2","key":"1547_CR111","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/107327481201900203","volume":"19","author":"RL Theriault","year":"2012","unstructured":"Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control. 2012;19(2):92\u2013101.","journal-title":"Cancer Control"},{"issue":"2","key":"1547_CR112","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"W Simonet","year":"1997","unstructured":"Simonet W, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309\u201319.","journal-title":"Cell"},{"issue":"3","key":"1547_CR113","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1677\/erc.1.00543","volume":"12","author":"G Clines","year":"2005","unstructured":"Clines G, Guise T. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer. 2005;12(3):549\u201383.","journal-title":"Endocr Relat Cancer"},{"key":"1547_CR114","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fonc.2018.00258","volume":"8","author":"B Yoo","year":"2018","unstructured":"Yoo B, Fuchs BC, Medarova Z. New directions in the study and treatment of metastatic cancer. Front Oncol. 2018;8:258\u2013258.","journal-title":"Front Oncol"},{"issue":"4","key":"1547_CR115","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s13277-013-0831-y","volume":"34","author":"H Fazilaty","year":"2013","unstructured":"Fazilaty H, et al. Crosstalk between breast cancer stem cells and metastatic niche: emerging molecular metastasis pathway? Tumor Biol. 2013;34(4):2019\u201330.","journal-title":"Tumor Biol"},{"issue":"2","key":"1547_CR116","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1615\/CritRevEukaryotGeneExpr.v12.i2.40","volume":"12","author":"D Chelouche Lev","year":"2002","unstructured":"Chelouche Lev D, Price JE. Therapeutic intervention with breast cancer metastasis. Crit Rev Eukaryot Gene Expr. 2002;12(2):137\u201350.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"2","key":"1547_CR117","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clbc.2014.10.006","volume":"15","author":"P Kawalec","year":"2015","unstructured":"Kawalec P, \u0141opuch S, Mikrut A. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis. Clin Breast Cancer. 2015;15(2):90-100.e1.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"1547_CR118","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers12030731","volume":"12","author":"C Pottier","year":"2020","unstructured":"Pottier C, et al. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers. 2020;12(3):731.","journal-title":"Cancers"},{"issue":"1","key":"1547_CR119","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-018-0797-x","volume":"17","author":"R Butti","year":"2018","unstructured":"Butti R, et al. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018;17(1):34.","journal-title":"Mol Cancer"},{"key":"1547_CR120","doi-asserted-by":"publisher","first-page":"153303382096214","DOI":"10.1177\/1533033820962140","volume":"19","author":"X Yang","year":"2020","unstructured":"Yang X, Wu D, Yuan S. Tyrosine kinase inhibitors in the combination therapy of HER2 positive breast cancer. Technol Cancer Res Treat. 2020;19:1533033820962140.","journal-title":"Technol Cancer Res Treat"},{"issue":"Suppl 5","key":"1547_CR121","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0959-8049(02)80597-4","volume":"38","author":"T Pawson","year":"2002","unstructured":"Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002;38(Suppl 5):S3-10.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1547_CR122","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11591240-000000000-00000","volume":"11","author":"B Escudier","year":"2011","unstructured":"Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D. 2011;11(2):113\u201326.","journal-title":"Drugs R D"},{"issue":"18","key":"1547_CR123","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1200\/JCO.2010.31.2975","volume":"29","author":"HS Rugo","year":"2011","unstructured":"Rugo HS, et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011;29(18):2459\u201365.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1547_CR124","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.mri.2006.09.041","volume":"25","author":"LJ Wilmes","year":"2007","unstructured":"Wilmes LJ, et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 2007;25(3):319\u201327.","journal-title":"Magn Reson Imaging"},{"key":"1547_CR125","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/CMAR.S74202","volume":"7","author":"O Gunnarsson","year":"2015","unstructured":"Gunnarsson O, et al. Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Cancer Manag Res. 2015;7:65\u201373.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1547_CR126","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12967-019-2047-4","volume":"17","author":"G Facchini","year":"2019","unstructured":"Facchini G, et al. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. J Transl Med. 2019;17(1):296.","journal-title":"J Transl Med"},{"issue":"22","key":"1547_CR127","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14(22):7272\u201383.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"1547_CR128","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.2174\/138161212802430468","volume":"18","author":"M Wehland","year":"2012","unstructured":"Wehland M, et al. Target-based anti-angiogenic therapy in breast cancer. Curr Pharm Des. 2012;18(27):4244\u201357.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"1547_CR129","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10549-010-1226-z","volume":"125","author":"C Isaacs","year":"2011","unstructured":"Isaacs C, et al. Phase I\/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat. 2011;125(1):137\u201343.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"1547_CR130","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000505521","volume":"98","author":"S Dattachoudhury","year":"2020","unstructured":"Dattachoudhury S, et al. Sorafenib inhibits proliferation, migration and invasion of breast cancer cells. Oncology. 2020;98(7):478\u201386.","journal-title":"Oncology"},{"issue":"8","key":"1547_CR131","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1634\/theoncologist.2012-0043","volume":"17","author":"S Reddy","year":"2012","unstructured":"Reddy S, Raffin M, Kaklamani V. Targeting angiogenesis in metastatic breast cancer. Oncologist. 2012;17(8):1014\u201326.","journal-title":"Oncologist"},{"issue":"4","key":"1547_CR132","doi-asserted-by":"publisher","first-page":"331","DOI":"10.5306\/wjco.v7.i4.331","volume":"7","author":"M Zafrakas","year":"2016","unstructured":"Zafrakas M, Papasozomenou P, Emmanouilides C. Sorafenib in breast cancer treatment: a systematic review and overview of clinical trials. World J Clin Oncol. 2016;7(4):331\u20136.","journal-title":"World J Clin Oncol"},{"issue":"2","key":"1547_CR133","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10549-016-4001-y","volume":"160","author":"SM Tolaney","year":"2016","unstructured":"Tolaney SM, et al. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Res Treat. 2016;160(2):305\u201312.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"1547_CR134","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298\u2013308.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1547_CR135","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18(1):153.","journal-title":"Mol Cancer"},{"issue":"6","key":"1547_CR136","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000261705","volume":"4","author":"C Mundhenke","year":"2009","unstructured":"Mundhenke C, Strauss A, Schem C. Significance of tyrosine kinase inhibitors in the treatment of metastatic breast cancer. Breast care (Basel, Switzerland). 2009;4(6):373\u20138.","journal-title":"Breast care (Basel, Switzerland)"},{"issue":"11","key":"1547_CR137","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","volume":"26","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26(11):1810\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1547_CR138","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13058-020-01346-y","volume":"22","author":"D Wang","year":"2020","unstructured":"Wang D, et al. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence. Breast Cancer Res. 2020;22(1):103.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1547_CR139","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/2159-8290.CD-14-0788","volume":"5","author":"CL Chaffer","year":"2015","unstructured":"Chaffer CL, Weinberg RA. How does multistep tumorigenesis really proceed? Cancer Discov. 2015;5(1):22\u20134.","journal-title":"Cancer Discov"},{"issue":"3","key":"1547_CR140","first-page":"383","volume":"7","author":"SH Hare","year":"2017","unstructured":"Hare SH, Harvey AJ. MTOR function and therapeutic targeting in breast cancer. Am J Cancer Res. 2017;7(3):383\u2013404.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"1547_CR141","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5306\/wjco.v8.i2.120","volume":"8","author":"V Masoud","year":"2017","unstructured":"Masoud V, Pag\u00e8s G. Targeted therapies in breast cancer: new challenges to fight against resistance. World J Clin Oncol. 2017;8(2):120\u201334.","journal-title":"World J Clin Oncol"},{"issue":"1","key":"1547_CR142","first-page":"38","volume":"27","author":"S Vinayak","year":"2013","unstructured":"Vinayak S, Carlson RW. mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park). 2013;27(1):38\u201344.","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"1547_CR143","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/bcp.12958","volume":"82","author":"LS Steelman","year":"2016","unstructured":"Steelman LS, et al. The therapeutic potential of mTOR inhibitors in breast cancer. Br J Clin Pharmacol. 2016;82(5):1189\u2013212.","journal-title":"Br J Clin Pharmacol"},{"issue":"26","key":"1547_CR144","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666\u201376.","journal-title":"N Engl J Med"},{"issue":"10","key":"1547_CR145","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/sj.bjc.6604741","volume":"99","author":"R Torrisi","year":"2008","unstructured":"Torrisi R, et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and\/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer. 2008;99(10):1564\u201371.","journal-title":"Br J Cancer"},{"issue":"12","key":"1547_CR146","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1947601912450586","volume":"2","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer. 2011;2(12):1159\u201365.","journal-title":"Genes Cancer"},{"issue":"10","key":"1547_CR147","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/ijc.25563","volume":"128","author":"T B\u00e4uerle","year":"2011","unstructured":"B\u00e4uerle T, et al. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer. 2011;128(10):2453\u201362.","journal-title":"Int J Cancer"},{"issue":"8","key":"1547_CR148","first-page":"3056","volume":"6","author":"JC Gutheil","year":"2000","unstructured":"Gutheil JC, et al. Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin \u03b1\u03bd\u03b23. Clin Cancer Res. 2000;6(8):3056\u201361.","journal-title":"Clin Cancer Res"},{"key":"1547_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/1477-3163.176223","volume":"15","author":"JM Casta\u00f1eda-Gill","year":"2016","unstructured":"Casta\u00f1eda-Gill JM, Vishwanatha JK. Antiangiogenic mechanisms and factors in breast cancer treatment. J Carcinogen. 2016;15:1\u20131.","journal-title":"J Carcinogen"},{"issue":"6","key":"1547_CR150","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0093-7754(01)90035-1","volume":"28","author":"P Falardeau","year":"2001","unstructured":"Falardeau P, et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001;28(6):620\u20135.","journal-title":"Semin Oncol"},{"issue":"2","key":"1547_CR151","first-page":"299","volume":"20","author":"MH Weber","year":"2002","unstructured":"Weber MH, Lee J, Orr FW. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol. 2002;20(2):299\u2013303.","journal-title":"Int J Oncol"},{"issue":"7","key":"1547_CR152","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/qjmed\/hch074","volume":"97","author":"AL Gill","year":"2004","unstructured":"Gill AL, Bell CN. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM. 2004;97(7):385\u201395.","journal-title":"QJM"},{"issue":"4","key":"1547_CR153","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11523-012-0233-x","volume":"7","author":"I Moen","year":"2012","unstructured":"Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer\u2013a review. Target Oncol. 2012;7(4):233\u201342.","journal-title":"Target Oncol"},{"issue":"8","key":"1547_CR154","doi-asserted-by":"publisher","first-page":"e0183254","DOI":"10.1371\/journal.pone.0183254","volume":"12","author":"K Yttersian Sletta","year":"2017","unstructured":"Yttersian Sletta K, et al. Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts. PLoS ONE. 2017;12(8):e0183254\u2013e0183254.","journal-title":"PLoS ONE"},{"key":"1547_CR155","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fonc.2018.00527","volume":"8","author":"JM Mast","year":"2018","unstructured":"Mast JM, Kuppusamy P. Hyperoxygenation as a therapeutic supplement for treatment of triple negative breast cancer. Front Oncol. 2018;8:527.","journal-title":"Front Oncol"},{"issue":"11","key":"1547_CR156","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3390\/nu10111756","volume":"10","author":"C Ceci","year":"2018","unstructured":"Ceci C, et al. Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid. Nutrients. 2018;10(11):1756.","journal-title":"Nutrients"},{"issue":"3","key":"1547_CR157","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0378-8741(02)00099-5","volume":"81","author":"A Saleem","year":"2002","unstructured":"Saleem A, et al. Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula retz. fruit. J Ethnopharmacol. 2002;81(3):327\u201336.","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"1547_CR158","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2174\/1566524015666150505161046","volume":"15","author":"L Shi","year":"2015","unstructured":"Shi L, et al. Ellagic acid enhances the efficacy of PI3K inhibitor GDC-0941 in breast cancer cells. Curr Mol Med. 2015;15(5):478\u201386.","journal-title":"Curr Mol Med"},{"issue":"3","key":"1547_CR159","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10549-012-1977-9","volume":"134","author":"N Wang","year":"2012","unstructured":"Wang N, et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res Treat. 2012;134(3):943\u201355.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"1547_CR160","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.2174\/138161210791034003","volume":"16","author":"I Holen","year":"2010","unstructured":"Holen I, Coleman RE. Bisphosphonates as treatment of bone metastases. Curr Pharm Des. 2010;16(11):1262\u201371.","journal-title":"Curr Pharm Des"},{"issue":"S12","key":"1547_CR161","first-page":"2961","volume":"88","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer Interdiscip Int J Am Cancer Soc. 2000;88(S12):2961\u201378.","journal-title":"Cancer Interdiscip Int J Am Cancer Soc"},{"issue":"3","key":"1547_CR162","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"G van der Pluijm","year":"1996","unstructured":"van der Pluijm G, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Investig. 1996;98(3):698\u2013705.","journal-title":"J Clin Investig"},{"issue":"11","key":"1547_CR163","first-page":"2949","volume":"60","author":"S Boissier","year":"2000","unstructured":"Boissier S, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Can Res. 2000;60(11):2949\u201354.","journal-title":"Can Res"},{"issue":"4","key":"1547_CR164","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/jnci\/djk054","volume":"99","author":"F Daubin\u00e9","year":"2007","unstructured":"Daubin\u00e9 F, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007;99(4):322\u201330.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1547_CR165","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","volume":"82","author":"S Senaratne","year":"2000","unstructured":"Senaratne S, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82(8):1459\u201368.","journal-title":"Br J Cancer"},{"issue":"10","key":"1547_CR166","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1182\/blood-2009-07-234211","volume":"116","author":"A Maniar","year":"2010","unstructured":"Maniar A, et al. Human \u03b3\u03b4 T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010;116(10):1726\u201333.","journal-title":"Blood"},{"issue":"13","key":"1547_CR167","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","volume":"71","author":"I Benza\u00efd","year":"2011","unstructured":"Benza\u00efd I, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote V\u03b39V\u03b42 T-cell chemotaxis and cytotoxicity in vivo. Can Res. 2011;71(13):4562\u201372.","journal-title":"Can Res"},{"issue":"27","key":"1547_CR168","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.2174\/138161210793563590","volume":"16","author":"SP Syddall","year":"2010","unstructured":"Syddall SP, Ottewell PD, Holen I. Combined therapies of bone disease with bisphosphonates. Curr Pharm Des. 2010;16(27):2988\u201397.","journal-title":"Curr Pharm Des"},{"issue":"28","key":"1547_CR169","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","volume":"25","author":"A Lipton","year":"2007","unstructured":"Lipton A, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25(28):4431\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1547_CR170","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","volume":"25","author":"JR Canon","year":"2008","unstructured":"Canon JR, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis. 2008;25(2):119\u201329.","journal-title":"Clin Exp Metastasis"},{"issue":"35","key":"1547_CR171","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139.","journal-title":"J Clin Oncol"},{"issue":"4766","key":"1547_CR172","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1126\/science.3090685","volume":"233","author":"MC Mossing","year":"1986","unstructured":"Mossing MC, Record MT Jr. Upstream operators enhance repression of the lac promoter. Science. 1986;233(4766):889\u201392.","journal-title":"Science"},{"issue":"9","key":"1547_CR173","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125\u201332.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1547_CR174","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082\u201392.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1547_CR175","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry D, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679\u201387.","journal-title":"Support Care Cancer"},{"issue":"6","key":"1547_CR176","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/ol.2014.1982","volume":"7","author":"X Wang","year":"2014","unstructured":"Wang X, et al. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials. Oncol Lett. 2014;7(6):1997\u20132002.","journal-title":"Oncol Lett"},{"key":"1547_CR177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003474.pub4","author":"MH Wong","year":"2012","unstructured":"Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2012. https:\/\/doi.org\/10.1002\/14651858.CD003474.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1547_CR178","first-page":"9","volume":"6","author":"RS Bora","year":"2012","unstructured":"Bora RS, et al. RNA interference therapeutics for cancer: challenges and opportunities (review). Mol Med Rep. 2012;6(1):9\u201315.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1547_CR179","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccr.2005.06.003","volume":"8","author":"W Tao","year":"2005","unstructured":"Tao W, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell. 2005;8(1):49\u201359.","journal-title":"Cancer Cell"},{"issue":"22","key":"1547_CR180","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-10-1994","volume":"16","author":"A Santel","year":"2010","unstructured":"Santel A, et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res. 2010;16(22):5469\u201380.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1547_CR181","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.tranon.2015.03.010","volume":"8","author":"X Liu","year":"2015","unstructured":"Liu X. Targeting polo-like kinases: a promising therapeutic approach for cancer treatment. Transl Oncol. 2015;8(3):185\u201395.","journal-title":"Transl Oncol"},{"issue":"2","key":"1547_CR182","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.onc.1208272","volume":"24","author":"N Takai","year":"2005","unstructured":"Takai N, et al. Polo-like kinases (Plks) and cancer. Oncogene. 2005;24(2):287\u201391.","journal-title":"Oncogene"},{"issue":"7","key":"1547_CR183","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1158\/0008-5472.CAN-04-2131","volume":"65","author":"R Guan","year":"2005","unstructured":"Guan R, et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res. 2005;65(7):2698\u2013704.","journal-title":"Cancer Res"},{"issue":"11","key":"1547_CR184","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/jnci\/djh146","volume":"96","author":"B Sp\u00e4nkuch","year":"2004","unstructured":"Sp\u00e4nkuch B, et al. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst. 2004;96(11):862\u201372.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1547_CR185","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1074\/jbc.M311153200","volume":"279","author":"G Yang","year":"2004","unstructured":"Yang G, et al. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2\/neu gene expression. J Biol Chem. 2004;279(6):4339\u201345.","journal-title":"J Biol Chem"},{"issue":"3","key":"1547_CR186","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/0008-5472.967.65.3","volume":"65","author":"Z Liang","year":"2005","unstructured":"Liang Z, et al. Silencing of CXCR4 blocks breast cancer metastasis. Can Res. 2005;65(3):967\u201371.","journal-title":"Can Res"},{"key":"1547_CR187","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7150\/oncm.26116","volume":"3","author":"A Huynh","year":"2018","unstructured":"Huynh A, Madu CO, Lu Y. siRNA: a promising new tool for future breast cancer therapy. Oncomedicine. 2018;3:74\u201381.","journal-title":"Oncomedicine"},{"key":"1547_CR188","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41698-019-0080-7","volume":"3","author":"X Tian","year":"2019","unstructured":"Tian X, et al. CRISPR\/Cas9: an evolving biological tool kit for cancer biology and oncology. NPJ Precis Oncol. 2019;3:8.","journal-title":"NPJ Precis Oncol"},{"key":"1547_CR189","doi-asserted-by":"publisher","first-page":"184954352098319","DOI":"10.1177\/1849543520983196","volume":"7","author":"J Padayachee","year":"2020","unstructured":"Padayachee J, Singh M. Therapeutic applications of CRISPR\/Cas9 in breast cancer and delivery potential of gold nanomaterials. Nanobiomedicine. 2020;7:1849543520983196.","journal-title":"Nanobiomedicine"},{"issue":"12","key":"1547_CR190","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/0008-5472.CAN-17-3470","volume":"78","author":"J Liu","year":"2018","unstructured":"Liu J, et al. Differential effects of estrogen receptor \u03b2 isoforms on glioblastoma progression. Cancer Res. 2018;78(12):3176\u201389.","journal-title":"Cancer Res"},{"issue":"1","key":"1547_CR191","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.gendis.2018.10.004","volume":"6","author":"G Pranavathiyani","year":"2018","unstructured":"Pranavathiyani G, et al. Integrated transcriptome interactome study of oncogenes and tumor suppressor genes in breast cancer. Genes & diseases. 2018;6(1):78\u201387.","journal-title":"Genes & diseases"},{"key":"1547_CR192","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2016.10.033","volume":"385","author":"H Wang","year":"2017","unstructured":"Wang H, Sun W. CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation. Cancer Lett. 2017;385:137\u201343.","journal-title":"Cancer Lett"},{"issue":"37","key":"1547_CR193","doi-asserted-by":"publisher","first-page":"18295","DOI":"10.1073\/pnas.1904697116","volume":"116","author":"P Guo","year":"2019","unstructured":"Guo P, et al. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. Proc Natl Acad Sci U S A. 2019;116(37):18295\u2013303.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1547_CR194","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41413-018-0009-8","volume":"6","author":"D Chen","year":"2018","unstructured":"Chen D, et al. Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res. 2018;6:11.","journal-title":"Bone Res"},{"issue":"2","key":"1547_CR195","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.celrep.2018.03.056","volume":"23","author":"J Schuijers","year":"2018","unstructured":"Schuijers J, et al. Transcriptional dysregulation of MYC reveals common enhancer-docking mechanism. Cell Rep. 2018;23(2):349\u201360.","journal-title":"Cell Rep"},{"issue":"3","key":"1547_CR196","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/biom7030053","volume":"7","author":"Y Fallah","year":"2017","unstructured":"Fallah Y, et al. MYC-driven pathways in breast cancer subtypes. Biomolecules. 2017;7(3):53.","journal-title":"Biomolecules"},{"key":"1547_CR197","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.2147\/OTT.S156143","volume":"11","author":"H Sun","year":"2018","unstructured":"Sun H, et al. SIRT4 acts as a tumor suppressor in gastric cancer by inhibiting cell proliferation, migration, and invasion. Onco Targets Ther. 2018;11:3959\u201368.","journal-title":"Onco Targets Ther"},{"issue":"11","key":"1547_CR198","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.molmed.2019.07.007","volume":"25","author":"C Jiang","year":"2019","unstructured":"Jiang C, Lin X, Zhao Z. Applications of CRISPR\/Cas9 technology in the treatment of lung cancer. Trends Mol Med. 2019;25(11):1039\u201349.","journal-title":"Trends Mol Med"},{"key":"1547_CR199","doi-asserted-by":"publisher","first-page":"41718","DOI":"10.1038\/srep41718","volume":"7","author":"K Xu","year":"2017","unstructured":"Xu K, et al. MFN2 suppresses cancer progression through inhibition of mTORC2\/Akt signaling. Sci Rep. 2017;7:41718.","journal-title":"Sci Rep"},{"issue":"36","key":"1547_CR200","doi-asserted-by":"publisher","first-page":"60210","DOI":"10.18632\/oncotarget.19417","volume":"8","author":"K Jin","year":"2017","unstructured":"Jin K, Pandey NB, Popel AS. Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis. Oncotarget. 2017;8(36):60210.","journal-title":"Oncotarget"},{"issue":"19","key":"1547_CR201","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1101\/gad.304261.117","volume":"31","author":"S Zhang","year":"2017","unstructured":"Zhang S, et al. Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase. Genes Dev. 2017;31(19):1939\u201357.","journal-title":"Genes Dev"},{"key":"1547_CR202","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.2147\/OTT.S195661","volume":"12","author":"M Yang","year":"2019","unstructured":"Yang M, et al. Impact of CXCR4 and CXCR7 knockout by CRISPR\/Cas9 on the function of triple-negative breast cancer cells. Onco Targets Ther. 2019;12:3849\u201358.","journal-title":"Onco Targets Ther"},{"key":"1547_CR203","doi-asserted-by":"publisher","first-page":"118525","DOI":"10.1016\/j.lfs.2020.118525","volume":"263","author":"A Hazafa","year":"2020","unstructured":"Hazafa A, et al. CRISPR\/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci. 2020;263:118525\u2013118525.","journal-title":"Life Sci"},{"issue":"53","key":"1547_CR204","doi-asserted-by":"publisher","first-page":"30173","DOI":"10.18632\/oncotarget.25734","volume":"9","author":"AM H\u00f8ye","year":"2018","unstructured":"H\u00f8ye AM, et al. Tumor endothelial marker 8 promotes cancer progression and metastasis. Oncotarget. 2018;9(53):30173\u201388.","journal-title":"Oncotarget"},{"issue":"6","key":"1547_CR205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr87","volume":"2","author":"DR Welch","year":"2000","unstructured":"Welch DR, Steeg PS, Rinker-Schaeffer CW. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res. 2000;2(6):1\u20139.","journal-title":"Breast Cancer Res"},{"issue":"40","key":"1547_CR206","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1038\/onc.2008.155","volume":"27","author":"A Calvo","year":"2008","unstructured":"Calvo A, et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008;27(40):5373\u201384.","journal-title":"Oncogene"},{"issue":"11","key":"1547_CR207","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2217\/fon.13.92","volume":"9","author":"DM Gilkes","year":"2013","unstructured":"Gilkes DM, Semenza GL. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 2013;9(11):1623\u201336.","journal-title":"Future Oncol"},{"issue":"1","key":"1547_CR208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"JY Lee","year":"2016","unstructured":"Lee JY, et al. Gene expression profiling of breast cancer brain metastasis. Sci Rep. 2016;6(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"3","key":"1547_CR209","doi-asserted-by":"publisher","first-page":"210","DOI":"10.20892\/j.issn.2095-3941.2018.0022","volume":"15","author":"MA Estiar","year":"2018","unstructured":"Estiar MA, Mehdipour P. ATM in breast and brain tumors: a comprehensive review. Cancer Biol Med. 2018;15(3):210.","journal-title":"Cancer Biol Med"},{"key":"1547_CR210","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2741\/e765","volume":"8","author":"SR Sirkisoon","year":"2016","unstructured":"Sirkisoon SR, et al. EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci. 2016;8:245.","journal-title":"Front Biosci"},{"issue":"1","key":"1547_CR211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-8-42","volume":"8","author":"N Bektas","year":"2008","unstructured":"Bektas N, et al. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer. 2008;8(1):1\u20139.","journal-title":"BMC Cancer"},{"key":"1547_CR212","doi-asserted-by":"crossref","unstructured":"Salhia, B., et al., Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS ONE, 2014. 9(1): p. e85448.","DOI":"10.1371\/journal.pone.0085448"},{"issue":"11","key":"1547_CR213","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","volume":"29","author":"X Wang","year":"2008","unstructured":"Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008;29(11):1275\u201388.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"1547_CR214","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00401-018-1806-2","volume":"135","author":"DA Mustafa","year":"2018","unstructured":"Mustafa DA, et al. T lymphocytes facilitate brain metastasis of breast cancer by inducing guanylate-binding protein 1 expression. Acta Neuropathol. 2018;135(4):581\u201399.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1547_CR215","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.bbagen.2017.03.016","volume":"1861","author":"W Fan","year":"2017","unstructured":"Fan W, et al. RUVBL1-ITFG1 interaction is required for collective invasion in breast cancer. Biochem Biophys Acta. 2017;1861(7):1788\u2013800.","journal-title":"Biochem Biophys Acta"},{"issue":"1","key":"1547_CR216","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1307-8","volume":"38","author":"R Zanin","year":"2019","unstructured":"Zanin R, et al. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1. J Exp Clin Cancer Res. 2019;38(1):1\u201323.","journal-title":"J Exp Clin Cancer Res"},{"key":"1547_CR217","first-page":"165","volume":"11","author":"MR Cominetti","year":"2019","unstructured":"Cominetti MR, Altei WF, Selistre-de-Araujo HS. Metastasis inhibition in breast cancer by targeting cancer cell extravasation. Breast Cancer. 2019;11:165.","journal-title":"Breast Cancer"},{"issue":"6","key":"1547_CR218","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3892\/or.2014.3516","volume":"32","author":"S Liu","year":"2014","unstructured":"Liu S, et al. Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2. Oncol Rep. 2014;32(6):2477\u201384.","journal-title":"Oncol Rep"},{"issue":"4","key":"1547_CR219","first-page":"205","volume":"6","author":"FA Malik","year":"2009","unstructured":"Malik FA, et al. Effect of expressional alteration of KAI1 on breast cancer cell growth, adhesion, migration and invasion. Cancer Genomics-Proteomics. 2009;6(4):205\u201313.","journal-title":"Cancer Genomics-Proteomics"},{"issue":"2","key":"1547_CR220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr2831","volume":"13","author":"MA Blanco","year":"2011","unstructured":"Blanco MA, Kang Y. Signaling pathways in breast cancer metastasis-novel insights from functional genomics. Breast Cancer Res. 2011;13(2):1\u20139.","journal-title":"Breast Cancer Res"},{"issue":"22","key":"1547_CR221","doi-asserted-by":"publisher","first-page":"10697","DOI":"10.18632\/aging.102485","volume":"11","author":"S Liu","year":"2019","unstructured":"Liu S, et al. MAP2K4 interacts with Vimentin to activate the PI3K\/AKT pathway and promotes breast cancer pathogenesis. Aging (Albany NY). 2019;11(22):10697.","journal-title":"Aging (Albany NY)"},{"issue":"9","key":"1547_CR222","doi-asserted-by":"publisher","first-page":"921","DOI":"10.18632\/oncotarget.626","volume":"3","author":"GJ Prud'homme","year":"2012","unstructured":"Prud\u2019homme GJ, Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget. 2012;3(9):921.","journal-title":"Oncotarget"},{"issue":"3","key":"1547_CR223","doi-asserted-by":"publisher","first-page":"e59772","DOI":"10.1371\/journal.pone.0059772","volume":"8","author":"J Bai","year":"2013","unstructured":"Bai J, et al. BRG1 is a prognostic marker and potential therapeutic target in human breast cancer. PLoS ONE. 2013;8(3):e59772.","journal-title":"PLoS ONE"},{"issue":"17","key":"1547_CR224","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/0008-5472.CAN-15-2322","volume":"76","author":"H Lee","year":"2016","unstructured":"Lee H, et al. TMEM2 Is a SOX4-regulated gene that mediates metastatic migration and invasion in breast cancer. Can Res. 2016;76(17):4994\u20135005.","journal-title":"Can Res"},{"issue":"6","key":"1547_CR225","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1615\/CritRevOncog.2014012000","volume":"19","author":"AE Yesilkanal","year":"2014","unstructured":"Yesilkanal AE, Rosner MR. Raf kinase inhibitory protein (RKIP) as a metastasis suppressor: regulation of signaling networks in cancer. Crit Rev Oncog. 2014;19(6):447\u201354.","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"1547_CR226","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1476-4598-9-179","volume":"9","author":"YL Chao","year":"2010","unstructured":"Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 2010;9(1):179.","journal-title":"Mol Cancer"},{"key":"1547_CR227","doi-asserted-by":"publisher","first-page":"124704","DOI":"10.1155\/2012\/124704","volume":"2012","author":"E Bevilacqua","year":"2012","unstructured":"Bevilacqua E, Frankenberger CA, Rosner MR. RKIP Suppresses breast cancer metastasis to the bone by regulating stroma-associated genes. Int J Breast Cancer. 2012;2012:124704.","journal-title":"Int J Breast Cancer."},{"issue":"2","key":"1547_CR228","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1593\/tlo.11268","volume":"5","author":"K Malinowsky","year":"2012","unstructured":"Malinowsky K, et al. UPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases. Transl Oncol. 2012;5(2):98\u2013104.","journal-title":"Transl Oncol"},{"issue":"1","key":"1547_CR229","doi-asserted-by":"publisher","first-page":"17608","DOI":"10.1038\/s41598-018-35710-y","volume":"8","author":"WD Mahauad-Fernandez","year":"2018","unstructured":"Mahauad-Fernandez WD, et al. BST-2 promotes survival in circulation and pulmonary metastatic seeding of breast cancer cells. Sci Rep. 2018;8(1):17608.","journal-title":"Sci Rep"},{"issue":"11","key":"1547_CR230","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/neuonc\/noy044","volume":"20","author":"RMSM Pedrosa","year":"2018","unstructured":"Pedrosa RMSM, et al. Breast cancer brain metastasis: molecular mechanisms and directions for treatment. Neuro Oncol. 2018;20(11):1439\u201349.","journal-title":"Neuro Oncol"},{"issue":"4","key":"1547_CR231","doi-asserted-by":"publisher","first-page":"677","DOI":"10.5306\/wjco.v5.i4.677","volume":"5","author":"RE Harris","year":"2014","unstructured":"Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol. 2014;5(4):677\u201392.","journal-title":"World J Clin Oncol"},{"issue":"3","key":"1547_CR232","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccell.2017.07.001","volume":"32","author":"B Strilic","year":"2017","unstructured":"Strilic B, Offermanns S. Intravascular survival and extravasation of tumor cells. Cancer Cell. 2017;32(3):282\u201393.","journal-title":"Cancer Cell"},{"issue":"1","key":"1547_CR233","first-page":"162","volume":"45","author":"X Wu","year":"2020","unstructured":"Wu X, Chen S, Lu C. Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway. Int J Mol Med. 2020;45(1):162\u201374.","journal-title":"Int J Mol Med"},{"issue":"17","key":"1547_CR234","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1128\/MCB.00356-06","volume":"26","author":"Q Fu","year":"2006","unstructured":"Fu Q, Manolagas SC, O\u2019Brien CA. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol. 2006;26(17):6453\u201368.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"1547_CR235","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12885-016-3033-3","volume":"17","author":"F Vesuna","year":"2017","unstructured":"Vesuna F, Bergman Y, Raman V. Genomic pathways modulated by Twist in breast cancer. BMC Cancer. 2017;17(1):52.","journal-title":"BMC Cancer"},{"issue":"20 Pt 2","key":"1547_CR236","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s\u20139s.","journal-title":"Clin Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01547-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01547-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01547-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T04:50:10Z","timestamp":1675572610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01547-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":236,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01547-1","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"8 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"95"}}